Search Results - "Frye, R F"

Refine Results
  1. 1

    Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes by Rotroff, DM, Shahin, MH, Gurley, SB, Zhu, H, Motsinger‐Reif, A, Meisner, M, Beitelshees, AL, Fiehn, O, Johnson, JA, Elbadawi‐Sidhu, M, Frye, RF, Gong, Y, Weng, L, Cooper‐DeHoff, RM, Kaddurah‐Daouk, R

    “…Achieving hypertension (HTN) control and mitigating the adverse health effects associated with HTN continues to be a global challenge. Some individuals respond…”
    Get full text
    Journal Article
  2. 2

    The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects by Hruska, M. W., Amico, J. A., Langaee, T. Y., Ferrell, R. E., Fitzgerald, S. M., Frye, R. F.

    Published in British journal of clinical pharmacology (01-01-2005)
    “…Aims Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the…”
    Get full text
    Journal Article
  3. 3

    DHEA and DHEA-S: A Review by Kroboth, Patricia D., Salek, Firoozeh S., Pittenger, Amy L., Fabian, Tanya J., Frye, Reginald F.

    Published in Journal of clinical pharmacology (01-04-1999)
    “…Dehydroepiandrosterone (DHEA) and its sulfated metabolite DHEA‐S are endogenous hormones secreted by the adrenal cortex in response to adrenocorticotrophin…”
    Get full text
    Journal Article
  4. 4

    Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity by Zgheib, N. K., Frye, R. F., Tracy, T. S., Romkes, M., Branch, R. A.

    Published in British journal of clinical pharmacology (01-04-2007)
    “…Aims We investigated flurbiprofen pharmacokinetics in 12 volunteers to develop a phenotypic trait measure that correlates with the fractional clearance to…”
    Get full text
    Journal Article
  5. 5

    Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes by Frye, Reginald F., Matzke, Gary R., Adedoyin, Adedayo, Porter, James A., Branch, Robert A.

    Published in Clinical pharmacology and therapeutics (01-10-1997)
    “…Objectives To determine whether the probe drugs caffeine, chlorzoxazone, dapsone, debrisoquin (INN, debrisoquine), and mephenytoin can be simultaneously…”
    Get full text
    Journal Article
  6. 6

    Concentration‐dependent response to pioglitazone in nonalcoholic steatohepatitis by Kawaguchi‐Suzuki, M., Bril, F., Kalavalapalli, S., Cusi, K., Frye, R. F.

    Published in Alimentary pharmacology & therapeutics (01-07-2017)
    “…Summary Background Pioglitazone is a safe and effective option to manage patients with type 2 diabetes and nonalcoholic steatohepatitis (NASH). However, there…”
    Get full text
    Journal Article
  7. 7

    Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis by Joy, MS, Matzke, GR, Frye, RF, Palevsky, PM

    Published in American journal of kidney diseases (01-06-1998)
    “…The clearance of vancomycin is significantly reduced in patients with acute, as well as, chronic renal failure. Although multiple-dosage regimen adjustment…”
    Get full text
    Journal Article
  8. 8

    Drug administration in patients with renal insufficiency : Minimising renal and extrarenal toxicity by MATZKE, G. R, FRYE, R. F

    Published in Drug safety (01-03-1997)
    “…Renal insufficiency has been associated with an increased risk of adverse effects with many classes of medications. The risk of some, but not all, adverse…”
    Get full text
    Journal Article
  9. 9

    Pharmacokinetics of intermittent intraperitoneal ceftazidime by Grabe, Darren W., Bailie, George R., Eisele, George, Frye, Reginald F.

    Published in American journal of kidney diseases (01-01-1999)
    “…Ceftazidime is currently recommended as an alternative first-line agent in the treatment of peritonitis and for Pseudomonas peritonitis. The pharmacokinetics…”
    Get full text
    Journal Article Conference Proceeding
  10. 10

    Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail by Adedoyin, Adedayo, Frye, Reginald F., Mauro, Kelly, Branch, Robert A.

    Published in British journal of clinical pharmacology (01-09-1998)
    “…Aims  The aim of this study was to investigate whether chloroquine can inhibit drug metabolism in humans, if such inhibition is general or selective for…”
    Get full text
    Journal Article Conference Proceeding
  11. 11

    Evaluation of the Influence of Diabetes Mellitus on Antipyrine Metabolism and CYP1A2 and CYP2D6 Activity by Matzke, Gary R., Frye, Reginald F., Early, John J., Straka, Robert J., Carson, Stanley W.

    Published in Pharmacotherapy (01-02-2000)
    “…Study Objective. To evaluate the metabolism of antipyrine, a general metabolic probe, caffeine, a probe for cytochrome P450 (CYP) 1A2 and N‐acetyltransferase…”
    Get full text
    Journal Article
  12. 12

    Cefazolin as empiric therapy in hemodialysis-related infections: Efficacy and blood concentrations by Marx, MA, Frye, RF, Matzke, GR, Golper, TA

    Published in American journal of kidney diseases (01-09-1998)
    “…Concern about the increasing incidence of vancomycin-resistant organisms has tempered the enthusiasm for indiscriminate vancomycin use. Cefazolin has an…”
    Get full text
    Journal Article
  13. 13

    Determinants of Ceftriaxone Clearance by Continuous Venovenous Hemofiltration and Hemodialysis by Matzke, Gary R., Frye, Reginald F., Joy, Melanie S., Palevsky, Paul M.

    Published in Pharmacotherapy (01-06-2000)
    “…Study Objective. To guide individual ceftriaxone dosages in patients receiving continuous renal replacement therapy. Design. Prospective, outpatient study…”
    Get full text
    Journal Article
  14. 14

    Effect of Ceftazidime on Systemic Cytokine Concentrations in Rats by ALKHARFY, Khalid M, KELLUM, John A, FRYE, Reginald F, MATZKE, Gary R

    Published in Antimicrobial Agents and Chemotherapy (01-11-2000)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  15. 15

    Sex Differences in the Pharmacokinetics of Dehydroepiandrosterone (DHEA) after Single- and Multiple-Dose Administration in Healthy Older Adults by Frye, Reginald F., Kroboth, Patricia D., Kroboth, Frank J., Stone, Roslyn A., Folan, Maggie, Salek, Firoozeh S., Pollock, Bruce G., Linares, Ana M., Hakala, Charles

    Published in Journal of clinical pharmacology (01-06-2000)
    “…The pharmacokinetics of exogenously administered DHEA have not been well characterized despite its increasing use in therapeutic and research investigations…”
    Get full text
    Journal Article
  16. 16

    Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients by Manley, HJ, Bailie, GR, Frye, RF, McGoldrick, MD

    Published in Peritoneal dialysis international (01-07-2001)
    “…School of Pharmacy, University of Missouri-Kansas City, USA. ManleyH@UMKC.edu…”
    Get full text
    Journal Article
  17. 17

    Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients by Elwell, R J, Manley, H J, Frye, R F, Bailie, G R

    Published in International journal of artificial organs (01-08-2005)
    “…Guidelines for empiric treatment of PD-related peritonitis published in 2000 recommend concurrent intraperitoneal (IP) cefazolin and ceftazidime. The…”
    Get full text
    Journal Article
  18. 18

    Effect of valerian, valerian/hops extracts, and valerenic acid on glucuronidation in vitro by Alkharfy, K. M., Frye, R. F.

    Published in Xenobiotica (01-02-2007)
    “…Valerian preparations alone or in combination with hops are popular over-the-counter products used for sleep disturbances or anxiety. Therefore, it is…”
    Get full text
    Journal Article
  19. 19
  20. 20

    The effect of age on the pharmacokinetics of the opioid antagonist nalmefene by FRYE, R. F., MATZKE, G. R., JALLAD, N. S., WILHELM, J. A., BIKHAZI, G. B.

    Published in British journal of clinical pharmacology (01-09-1996)
    “…1The disposition of nalmefene was evaluated in young and elderly normal healthy volunteers. Subjects received either a single 1 mg (n=18 young; n=11 elderly)…”
    Get full text
    Journal Article